Not exact matches
A team of researchers from the Hyperbaric Biomedical Research
Laboratory at the University of South Florida (USF) doubled survival time in an aggressive metastatic cancer
model using a
novel combination of non-toxic dietary and hyperbaric oxygen therapies.
«This study showed the value of interdisciplinary collaboration through a
novel combination of
laboratory, observational and
modeling work.»
In testing on
laboratory mouse
models and human MDS / AML samples, the researchers identified a
novel substrate of TRAF6 called hnRNPA1, an RNA binding protein.
Through the integration of such large - scale data sets within computational
models, his
laboratory is unraveling condition - dependent networks of active regulation process and
novel principles on the operation of metabolic networks.
The Bergthaler
laboratory pursues an integrative approach comprising infection
models and tools of immunology, pathology and systems biology in order to dissect
novel disease - relevant interactions between pathogens and the host.
Because of the ease with which the CRISPR / Cas9 system can be applied, it has quickly become a robust tool for generating accurate genetic disease
models in the
laboratory and for identifying
novel therapeutic targets in the clinic.
Dr. Jason Yustein's research
laboratory is utilizing tissue - specific expression of an oncogenic p53 mutant to form
novel, applicable transgenic mouse
models of metastatic osteosarcoma and rhabdomyosarcoma, both conditions that have particularly poor patient outcmes.
«Our findings reveal a critical role for telomere length in a mouse
model of age - dependent human disease,» said first author Christina Theodoris, an MD / PhD student in the
laboratory of Deepak Srivastava, MD. «This
model provides a unique opportunity to dissect the mechanisms by which telomeres affect age - dependent disease and also a system to test
novel therapeutics for aortic valve disease.»
He has developed
laboratory and animal
models of the tumor in its microenvironment, which have allowed for both identification of
novel targets and validation of
novel targeted therapies.